2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pain
5
Colorectal Neoplasms
5
Neoplasms
4
Breast Neoplasms
4
Stomatitis
3
Neoplasm Metastasis
3
Adenoma
3
Urologic Neoplasms
2
Stomach Neoplasms
2
Mucositis
2
Insulin Resistance
2
Head and Neck Neoplasms
2
Vulvodynia
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
Melanoma
1
MRSA Colonization
1
Interventions
Oxaliplatin
271
Fluorouracil
268
Capecitabine
234
Leucovorin
209
Irinotecan
152
Radiotherapy
138
Bevacizumab
114
Cetuximab
82
Surgical Procedures, Operative
51
Folfox protocol
48
Neoadjuvant Therapy
45
Drug Therapy
43
Radiation
42
Chemotherapy, Adjuvant
34
Chemoradiotherapy
34
Panitumumab
27
Magnetic Resonance Spectroscopy
26
XELOX
25
Radiotherapy, Intensity-Modulated
23
Biopsy
20
Surveys and Questionnaires
18
Laparoscopy
18
Proctectomy
17
Floxuridine
17
Early Intervention, Educational
16
Nivolumab
15
Immunohistochemistry
15
Gene Expression Profiling
15
Gemcitabine
15
pembrolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled